These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12375030)

  • 1. Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
    Stathopoulos GP
    Oncol Rep; 2002; 9(6):1257-9. PubMed ID: 12375030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting tyrosine kinases: successes and limitations.
    Arteaga CL
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S79-83. PubMed ID: 14508084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
    Mills GB; Kohn E; Lu Y; Eder A; Fang X; Wang H; Bast RC; Gray J; Jaffe R; Hortobagyi G
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):93-104. PubMed ID: 14613030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer treatment. New drugs, new hope.
    Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib: a selective tyrosine kinase inhibitor.
    Manley PW; Cowan-Jacob SW; Buchdunger E; Fabbro D; Fendrich G; Furet P; Meyer T; Zimmermann J
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S19-27. PubMed ID: 12528769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Researchers optimistic about sea change in cancer treatment.
    Stephenson J
    JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational therapeutic intervention in cancer: kinases as drug targets.
    Sawyers CL
    Curr Opin Genet Dev; 2002 Feb; 12(1):111-5. PubMed ID: 11790564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond Herceptin and Gleevec.
    Fischer OM; Streit S; Hart S; Ullrich A
    Curr Opin Chem Biol; 2003 Aug; 7(4):490-5. PubMed ID: 12941424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for the treatment of cancer.
    Kim JA
    Am J Surg; 2003 Sep; 186(3):264-8. PubMed ID: 12946830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
    Gambacorti C
    Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
    [No Abstract]   [Full Text] [Related]  

  • 16. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.
    Smith JK; Mamoon NM; Duhé RJ
    Oncol Res; 2004; 14(4-5):175-225. PubMed ID: 14977353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors: a clinical perspective.
    Goel S; Mani S; Perez-Soler R
    Curr Oncol Rep; 2002 Jan; 4(1):9-19. PubMed ID: 11734109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.